Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director | June 11, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 159,760 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 35,000 · Balance 159,760 F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the Company's Board of Directors on such dates. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the Company's Board of Directors on such dates.
F2: Includes shares of restricted common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 16:10 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073455 · tm2617536-1_4seq1.xml · nonDerivative · entry 1 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,760 F1 · shares: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the Company's Board of Directors on such dates. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 08:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 11,000 | $5.84 | $64,240.00 |
DisclosureSEC source: 0001104659-25-107418 · tm2530379-1_4seq1.xml · nonDerivative · entry 1 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,760 F1 · shares: Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.81 to $5.88. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 16:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058919 · tm2517867-3_4seq1.xml · nonDerivative · entry 1 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,760 F1 · shares: The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the Company's Board of Directors on such dates. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 16:22 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071289 · tm2416958-3_4seq1.xml · nonDerivative · entry 1 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,760 F1 · shares: The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the board on such dates. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 08:16 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072606 · tm2319007-2_4seq1.xml · nonDerivative · entry 1 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,760 F1 · shares: The 18,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Kaplan's continued service on the board on such dates. Read SEC document |
| May 12, 2022 Filed May 16, 2022 08:32 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,823 | $17.47 | $31,847.81 |
DisclosureSEC source: 0001104659-22-060910 · tm2215423d2_4.xml · nonDerivative · entry 2 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,760 F2 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.33 to $17.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 12, 2022 Filed May 16, 2022 08:32 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,177 | $15.96 | $18,784.92 |
DisclosureSEC source: 0001104659-22-060910 · tm2215423d2_4.xml · nonDerivative · entry 1 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,937 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.75 to $16.00. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:48 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001104659-22-042821 · tm2211420-6_4seq1.xml · derivative · entry 1 Kaplan Matthew L. · CIK 0001895952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-04-01 F1 · derivative.exercise_date: The options will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.